Literature DB >> 19006559

The neurogenic basis of migraine.

F Michael Cutrer1, Andrew Charles.   

Abstract

There is accumulating evidence of a neurogenic basis of migraine. This evidence arises from both the clinical and experimental domains. Many of the well known clinical features of migraine attacks including the prodrome are not explained by changes in vascular caliber. Despite the fact that ergotamines and triptans are vasoactive does not provide substantive proof that vasoconstriction is their most important mechanism of action. Several effective treatments for migraine, both old and new, do not affect vascular caliber. Experimental evidence from investigation of both the aura and headache phases of migraine clearly supports a neural basis of migraine. All genes thus far conclusively associated with hemiplegic migraine code for neural proteins.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19006559     DOI: 10.1111/j.1526-4610.2008.01277.x

Source DB:  PubMed          Journal:  Headache        ISSN: 0017-8748            Impact factor:   5.887


  12 in total

Review 1.  Triptans for the management of migraine.

Authors:  Mollie M Johnston; Alan M Rapoport
Journal:  Drugs       Date:  2010-08-20       Impact factor: 9.546

Review 2.  Migraine pain: reflections against vasodilatation.

Authors:  Alessandro Panconesi; Maria Letizia Bartolozzi; Leonello Guidi
Journal:  J Headache Pain       Date:  2009-06-05       Impact factor: 7.277

3.  Matrix metalloproteinases in neuropathic pain and migraine: friends, enemies, and therapeutic targets.

Authors:  Shaheen E Lakhan; Mihaela Avramut
Journal:  Pain Res Treat       Date:  2012-08-28

4.  Preventive effect of greater occipital nerve block on severity and frequency of migraine headache.

Authors:  Davood Kashipazha; Ali Nakhostin-Mortazavi; Seyyed Ehsan Mohammadianinejad; Mohammad Bahadoram; Sepideh Zandifar; Shahram Tarahomi
Journal:  Glob J Health Sci       Date:  2014-07-29

5.  A 'complex' of brain metabolites distinguish altered chemistry in the cingulate cortex of episodic migraine patients.

Authors:  L Becerra; R Veggeberg; A Prescot; J E Jensen; P Renshaw; S Scrivani; E L H Spierings; R Burstein; D Borsook
Journal:  Neuroimage Clin       Date:  2016-03-31       Impact factor: 4.881

6.  The Cyclic Vomiting Syndrome Threshold: A Framework for Understanding Pathogenesis and Predicting Successful Treatments.

Authors:  David J Levinthal
Journal:  Clin Transl Gastroenterol       Date:  2016-10-27       Impact factor: 4.488

7.  Comparison of granisetron and metoclopramide in the treatment of pain and emesis in migraine patients: A randomized controlled trial study.

Authors:  Hassan Amiri; Niloufar Ghodrati; Mehrnaz Nikuyeh; Samad Shams-Vahdati; Mehran Jalilzadeh-Binazar
Journal:  Turk J Emerg Med       Date:  2017-01-10

8.  Vagus nerve stimulation for primary headache disorders: An anatomical review to explain a clinical phenomenon.

Authors:  Dylan Jozef Hendrik Augustinus Henssen; Berend Derks; Mats van Doorn; Niels Verhoogt; Anne-Marie Van Cappellen van Walsum; Peter Staats; Kris Vissers
Journal:  Cephalalgia       Date:  2019-02-20       Impact factor: 6.292

Review 9.  Cyclic vomiting syndrome: Pathophysiology, comorbidities, and future research directions.

Authors:  William L Hasler; David J Levinthal; Sally E Tarbell; Kathleen A Adams; B U K Li; Robert M Issenman; Irene Sarosiek; Safwan S Jaradeh; Ravi N Sharaf; Shahnaz Sultan; Thangam Venkatesan
Journal:  Neurogastroenterol Motil       Date:  2019-06       Impact factor: 3.598

Review 10.  The potential of lasmiditan in migraine.

Authors:  Jasper Mecklenburg; Bianca Raffaelli; Lars Neeb; Margarita Sanchez Del Rio; Uwe Reuter
Journal:  Ther Adv Neurol Disord       Date:  2020-10-21       Impact factor: 6.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.